Nautilus Biotechnology, Inc.
NAUT
$0.08
Change (1 day)
$3.46
Year High
$2.19
Year Low
Categories
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
P/E ratio for Nautilus Biotechnology, Inc. (NAUT)
P/E ratio as of 2023: -5.87
According to Nautilus Biotechnology, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.87. At the end of 2022 the company had a P/E ratio of -3.52.
P/E ratio history for Nautilus Biotechnology, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -5.87 |
| 2022 | -3.52 |
| 2021 | -8.70 |
| 2020 | -20.81 |
| 2019 | -7801.78 |
| 2018 | 0.12 |